Evolus, Inc. EOLS
We take great care to ensure that the data presented and summarized in this overview for Evolus, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EOLS
View all-
Nantahala Capital Management, LLC New Canaan, CT5.73MShares$41.3 Million1.43% of portfolio
-
Tang Capital Management LLC San Diego, CA5.49MShares$39.6 Million1.53% of portfolio
-
Black Rock Inc. New York, NY4.01MShares$28.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.43MShares$24.8 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA2.63MShares$19 Million0.68% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.86MShares$13.4 Million0.01% of portfolio
-
Stonepine Capital Management, LLC Bend, OR1.54MShares$11.1 Million7.67% of portfolio
-
State Street Corp Boston, MA1.52MShares$10.9 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY1.48MShares$10.7 Million0.7% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.45MShares$10.5 Million0.54% of portfolio
Latest Institutional Activity in EOLS
Top Purchases
Top Sells
About EOLS
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Insider Transactions at EOLS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 08
2025
|
Tatjana Mitchell Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
104,603
+50.0%
|
-
|
|
Aug 22
2025
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
5,722
-5.98%
|
$40,054
$7.51 P/Share
|
|
Aug 15
2025
|
Brady Stewart Director |
BUY
Open market or private purchase
|
Direct |
30,000
+25.29%
|
$180,000
$6.82 P/Share
|
|
Jun 16
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
16,582
-4.35%
|
$149,238
$9.89 P/Share
|
|
Jun 13
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
111,323
-22.59%
|
$1,113,230
$10.05 P/Share
|
|
Jun 09
2025
|
Albert G White Iii Director |
BUY
Open market or private purchase
|
Direct |
20,000
+28.42%
|
$180,000
$9.45 P/Share
|
|
May 13
2025
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,494
-3.74%
|
$64,940
$10.02 P/Share
|
|
May 12
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
15,787
-3.1%
|
$142,083
$9.87 P/Share
|
|
May 12
2025
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
3,385
-0.93%
|
$30,465
$9.87 P/Share
|
|
Mar 27
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
6,251
-1.21%
|
$75,012
$12.4 P/Share
|
|
Mar 18
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
103,376
-16.72%
|
$1,343,888
$13.26 P/Share
|
|
Mar 18
2025
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
4,536
-4.53%
|
$58,968
$13.26 P/Share
|
|
Mar 18
2025
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,996
-4.93%
|
$116,948
$13.26 P/Share
|
|
Mar 18
2025
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
27,904
-7.15%
|
$362,752
$13.26 P/Share
|
|
Mar 12
2025
|
Karah Herdman Parschauer Director |
SELL
Open market or private sale
|
Direct |
12,888
-28.59%
|
$154,656
$12.99 P/Share
|
|
Mar 07
2025
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,663
+16.34%
|
-
|
|
Mar 07
2025
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,832
+15.11%
|
-
|
|
Mar 07
2025
|
Karah Herdman Parschauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+14.04%
|
-
|
|
Mar 07
2025
|
Vikram Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+2.82%
|
-
|
|
Mar 07
2025
|
Albert G White Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+19.51%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 321K shares |
|---|---|
| Open market or private purchase | 50K shares |
| Open market or private sale | 338K shares |
|---|